INDIAN GOVERNMENT COMMITTEE SAYS "NO" TO DATA EXCLUSIVITY
After multiple deliberations spanning more than 3 years, a government committee has finally submitted its report on regulatory data protection and Article 39.3 of TRIPS. It finds that Article 39.3 does not require “data exclusivity” and that, at the present moment, it may not be in India’s national interest to grant “data exclusivity” to pharmaceutical drug data. It relies heavily on the Doha Declaration to support this interpretation. It argues that a “trade secrecy” form of protection is sufficient to …
INDIAN GOVERNMENT COMMITTEE SAYS "NO" TO DATA EXCLUSIVITY Read More »